top of page



Cambridge, UK – 25 March, 2020 – BIOS, a full-stack neural interface platform startup, has announced that Professor Joanne Hackett has been appointed as chair of the board. Professor Hackett brings over 20 years of experience and leadership roles in the biotech and life sciences sector. An accomplished entrepreneur, scientist, and strategist, she has deep expertise in scaling and commercialising biotech innovations.


"BIOS is an agile, fast paced and ambitious entrepreneurial biotech. These are crucial characteristics of successful early stage companies. The interface between technology and the human body is one of the most important fields helping us move beyond incremental changes to our approach to health. The platform that BIOS is developing could lead to a much bigger step change and is something I could not wait to be a part of," said Professor Hackett. "I have been fortunate enough to develop a global portfolio of companies I am involved with, each of which presents a unique challenge and a tremendous opportunity to learn. I look forward to helping BIOS realise its potential, and I am excited by the opportunity to learn more about such an exciting field."


Emil Hewage, CEO and co-founder of BIOS, said: “Professor Hackett’s background as a clinical researcher and senior executive at both Fortune 500 companies and startups have given her a unique ability to identify innovations and bring them to maturity. As one of the key global figures in personalised medicine, she immediately enhances the presence of BIOS in the sector. She is an experienced and highly skilled operator, and we’re thrilled to have her support and guidance as we continue our rapid growth.”


BIOS, founded 2015, and backed by UK and North American investors, is now entering its clinical development phase and is laying the groundwork for commercialisation of its technology. At this pivotal stage of growth, Professor Hackett’s experience and skills will be an invaluable addition.

About BIOS Health

BIOS is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals. The human nervous system carries vast quantities of data and scientists have long known that faulty signals in the nervous system play a key role in driving chronic diseases. By understanding and correcting these signals in real time, BIOS can treat chronic illnesses in an effective, automated, and personalised way. BIOS has leveraged recent breakthroughs in AI and Machine Learning to translate the “language” of the nervous system for the first time. BIOS’ neural code is built on the world’s largest proprietary neural data set and is already in use clinically to enhance data from wearables used in remote chronic disease care.

Co-founded by Cambridge University graduates Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology, and medicine. The combined experience of the BIOS team extends to over 300 peer-reviewed publications, 10+ First of kind medical devices and 6k+ clinical procedures.


Media contact

Hailey Eustace 

Head of Communications 

BIOS Health 

bottom of page